Promising cocktail targets tough lung cancer

NCT ID NCT06838208

Disease control Sponsor: Anhui Provincial Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether adding an immunotherapy drug (tislelizumab) to standard chemotherapy and radiation can help people with extensive small cell lung cancer live longer without their cancer getting worse. About 56 adults who have not had prior treatment for this advanced cancer will receive the combination. The main goal is to see how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: tislelizumab (an immunotherapy drug) combined with chemotherapy (carboplatin or cisplatin plus etoposide) and radiotherapy
What this could lead to: If successful, this could offer a new first-line treatment option that may help control extensive small cell lung cancer for longer than current therapies.
What could go wrong: This is an early Phase 2 trial with only 56 participants, so results may not apply to all patients. The combination also carries risks of side effects from chemotherapy, immunotherapy, and radiation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 56 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2025

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age≥18 years old, male or female, signed Informed Consent Form (ICF); 2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; 3. Histologically or cytologically confirmed ES-SCLC; 4. No prior systemic treatment for ES-SCLC; 5. At least one measurable (RECIST 1.1) chest lesion capable of 15Gy/5f irradiation; 6. Adequate hematologic and end organ function; Exclusion Criteria: 1. Active leptomeningeal disease or uncontrolled, untreated brain metastasis; 2. Prior therapy with an antibody or drug against immune checkpoint pathways, including but not limited to, anti program death receptor-1 (anti-PD-1), anti-PD-L1, or anti cytotoxic T lymphocyte associated antigen 4 (anti CTLA-4) antibody; 3. Was administered a live vaccine ≤ 4 weeks before treatment; 4. Active autoimmune diseases or history of autoimmune diseases that may relapse; 5. Any condition that required systemic treatment with either corticosteroids or other immunosuppressive medication ≤ 14 days before treatment; 6. With a history of interstitial lung disease, non-infectious pneumonitis, or uncontrolled systemic diseases; 7. Severe chronic or active infections requiring systemic antibacterial, antifungal or antiviral therapy within 2 weeks prior to treatment, including but not limited to tuberculosis infection; 8. Received therapeutic oral or intravenous (IV) antibiotics within 2 weeks prior to starting treatment;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Extensive-stage small cell lung cancer (es-SCLC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Extensive-stage small cell lung cancer (es-SCLC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

1 site. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Promising cocktail targets tough lung cancer

What the study statuses mean